The Role of Serum Soluble Urokinase-Type Plasminogen Activator Receptor in Stable Chronic Obstructive Pulmonary Disease

Can, Ummugulsum; Güzelant, Asuman; Yerlikaya, Fatma Hümeyra; Yosunkaya, Şebnem

doi:10.1097/jim.0000000000000105

Cited by 17 publications

(27 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, we infer that the validity of the developed prognostication score remains constant even if suPAR is not measured during the very first days after ICU admission due to the stability of suPAR concentrations over the disease course. These findings were comparable to other diseases including chronic obstructive pulmonary disease (COPD) [ 21 ] or acute respiratory distress syndrome (ARDS) [ 22 ], in which suPAR was regarded as an independent predictor for unfavorable outcomes.…”

Section: Discussionsupporting

confidence: 75%

Prognostic significance of APACHE II score and plasma suPAR in Chinese patients with sepsis: a prospective observational study

Shen

Liu

et al. 2015

BMC Anesthesiol

View full text Add to dashboard Cite

BackgroundTimely risk stratification is the key strategy to improve prognosis of patients with sepsis. Previous study has proposed to develop a powerful risk assessment rule by the combination of Acute Physiology and Chronic Health Evaluation II (APACHE II) score and plasma soluble urokinase plasminogen activator receptor (suPAR). That reaffirmation of suPAR as a prognostic marker in Chinese patients with severe sepsis is the aim of the study.MethodsA total of 137 consecutive Chinese patients with sepsis were enrolled in a prospective study cohort. Demographic and clinical characteristics, conventional risk factors and important laboratory data were prospectively recorded. Sequential plasma suPAR concentrations were measured by an enzymeimmunoabsorbent assay on days 1, 3, and 7 after admission to the intensive care unit (ICU). Receiver operating characteristic (ROC) curves and Cox regression analysis were used to examine the performance of suPAR in developing a rule for risk stratification.ResultsThe results showed that plasma suPAR concentrations remained relatively stable within survivors and non-survivors during the first week of disease course. Regression analysis indicated that APACHE II ≥15 and suPAR ≥10.82 ng/mL were independently associated with unfavorable outcome. With the above cutoffs of APACHE II and suPAR, strata of disease severity were determined. The mortality of each stratum differed significantly from the others.ConclusionsCombination of APACHE II score and suPAR may supply the powerful prognostic utility for the mortality of sepsis.

show abstract

Section: Discussionsupporting

confidence: 75%

Prognostic significance of APACHE II score and plasma suPAR in Chinese patients with sepsis: a prospective observational study

Shen

Liu

et al. 2015

BMC Anesthesiol

View full text Add to dashboard Cite

show abstract

“…These events are associated with airway and systemic inflammatory responses, and not surprisingly elevated suPAR levels were found during exacerbations [ 12 , 13 ]. The results in stable disease are contradictory, as both higher [ 14 ] and similar [ 15 ] levels were found. Comparing the two studies, the most striking difference was observed in the severity of airflow limitation, as Wang et al recruited participants with milder severity [ 15 ].…”

Section: Discussionmentioning

confidence: 94%

“…So far, only few studies have investigated suPAR in COPD, mainly focusing on acute exacerbations and reporting elevated levels [ 12 , 13 ]. In stable disease, Can et al reported higher serum suPAR levels compared to controls [ 14 ]. This contradicts a study by Wang et al who did not find significant difference between COPD and those in a healthy condition [ 15 ].…”

Section: Introductionmentioning

confidence: 99%

“…This contradicts a study by Wang et al who did not find significant difference between COPD and those in a healthy condition [ 15 ]. The discrepancy may be due to the relatively mild disease severity of the latter study [ 15 ], as the former study assessed patients with a wider range of lung function [ 14 ]. In addition, a number of factors which characterize disease burden apart from lung function, including symptom burden, exacerbation history and arterial stiffness, has not been assessed.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD

Bocskei

Benczúr

Losonczy

et al. 2019

Lung

View full text Add to dashboard Cite

Introduction Soluble urokinase-type plasminogen activator receptor (suPAR) is upregulated by inflammation and plays a role in the pathogenesis of atherosclerosis. Chronic obstructive pulmonary disease (COPD) is associated with enhanced systemic inflammation and increased risk for atherosclerosis, however, studies analysing the circulating suPAR levels in COPD are contradictory. The aim of the study was to investigate plasma suPAR concentrations together with markers of arterial stiffness in COPD. Materials and Methods Twenty-four patients with COPD and 18 non-COPD, control subjects participated in the study. Plasma suPAR was measured, together with lung volumes, symptom burden, exacerbation history, markers of arterial stiffness and soluble inflammatory biomarkers, such as endothelin-1, high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6). Results Plasma suPAR levels were higher in COPD (2.84 ± 0.67 ng/ml vs. 2.41 ± 0.57 ng/ml, p = 0.03) and were related to lung function measured with FEV 1 ( r = − 0.65, p < 0.01) and symptom burden determined with the modified Medical Research Council questionnaire ( r = 0.55, p < 0.05). Plasma suPAR concentrations correlated with various measures of arterial stiffness in all subjects, but only with ejection duration in COPD ( r = − 0.44, p = 0.03). Conclusions Plasma suPAR levels are elevated in COPD and relate to arterial stiffness. Our results suggest that suPAR may be a potential link between COPD and atherosclerosis.

show abstract

“…The levels of serum suPAR and plasma fibrinogen may be beneficial in the assessment of stable COPD [15] . Other researchers also emphasize that suPAR has a significant influence on lung diseases.…”

Section: Introductionmentioning

confidence: 99%

Soluble urokinase-type plasminogen activator receptor (suPAR) in multiple respiratory diseases

2015

Receptor Clin Invest

View full text Add to dashboard Cite

Serum soluble urokinase-type plasminogen activator receptor (suPAR) is a glycoprotein secreted during infections and inflammation [1] . Urokinase-type plasminogen activator (uPA) is secreted by polymorphonuclear neutrophils (PMN) and macrophages; then uPA binds to membrane urokinase-type plasminogen activator receptor (uPAR) [2] . suPAR is formed by cleaved from the uPAR [2] . suPAR is expressed in various cell types, such as macrophages monocytes, endothelial cells and neutrophils [3] . suPAR can be potentially cause or modulate various diseases in patients with cancer, various infectious and inflammatory diseases (including infections with human immunodeficiency virus (HIV), tuberculosis, liver fibrosis and inflammatory bowel disease) [2,3] . suPAR can convert plasminogen to plasmin, which degrades fibrin, activates matrix metalloproteases and mediates proteolysis of extracellular matrix proteins during cellular invasion [4] . suPAR modulate the functions of integrins (including activating intracellular signals, monocyte chemotaxis, cell adhesion and proliferation) [4,5] . So suPAR contributes to cell adhesion, migration, proliferation inflammation, chemotaxis, proteolysis, immune system activation, tissue remodeling and signal transduction [5,6] . Several studies have identified that suPAR level is a important marker in patients with various diseases and associated with a poorer outcome in a range of non-infectious and infectious diseases [2] . Biomarkers of lung disease are required to aid diagnosis, define clinical phenotypes and monitor the response to existing and new therapeutic strategies. Our review aims to explore the potential of suPAR as a general marker in the diagnosis, prognosis and follow-up of therapy of lung disease.To cite this article: Ummugulsum Can. The role of soluble urokinase-type plasminogen activator receptor (suPAR) in multiple respiratory diseases. Receptor Clin Invest 2015; 2: e473.

show abstract

The Role of Serum Soluble Urokinase-Type Plasminogen Activator Receptor in Stable Chronic Obstructive Pulmonary Disease

Cited by 17 publications

References 31 publications

Prognostic significance of APACHE II score and plasma suPAR in Chinese patients with sepsis: a prospective observational study

Prognostic significance of APACHE II score and plasma suPAR in Chinese patients with sepsis: a prospective observational study

Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD

Soluble urokinase-type plasminogen activator receptor (suPAR) in multiple respiratory diseases

Contact Info

Product

Resources

About